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ABSTRACT 
The objectives of the study were to evaluate the impact of a newly developed pharmaceutical 
care services directed to rheumatoid arthritis patients attending an out-patient setting.  A total of 
88 patients participated in the study and were randomly divided into two equal groups, Group A 
and Group B.  The study was carried out over three phases. In phase 1 (time 0), Group A patients 
were assessed and offered a pharmaceutical care session. Group B patients were assessed but no 
pharmaceutical care session was delivered.  At phase 2 (4-6 months), group A patients were re-
assessed (first assessment post pharmaceutical care plan).  Group B patients were re-assessed a 
second time (second baseline assessment) and a pharmaceutical care session was offered to 
Group B patients.  At phase 3 (time 10-11 months) both groups were re-assessed a third time. 
The Health Assessment Questionnaire and the Short Form-36 were used as outcome measures 
during each assessment.  There were statistically significant differences (p<0.05) in all the 8 
domains of the SF-36 between Phase 1 and 3 for both groups.  For the Health Assessment 
Questionnaire, a statistical improvement in the daily activities was identified after the 
pharmaceutical care intervention for both groups (Phase 2 for Group A and phase 3 for Group 
B). The newly developed individualised pharmaceutical care service provided by the pharmacist 
led to an improved quality of life as measured by the health related quality of life questionnaires. 
Keywords: pharmaceutical care, quality of life, rheumatoid arthritis, drug therapy problems, 
pharmacist contribution 
 
 
 
 
 
*Corresponding Author Email: louise.grech@um.edu.mt 
Received 07 September 2013, Accepted 16 September 2013 
 
Louise et. al.,  Am. J. Pharm Health Res 2013;1(7)     ISSN: 2321-3647 
www.ajphr.com   79 
 
INTRODUCTION 
Rheumatoid arthritis affects approximately 0.3-1% of the population in developing countries
1-2
.  
It is a chronic autoimmune systemic inflammatory disorder of the joints characterized by 
potentially deforming symmetrical polyarthritis and accompanied by extra-articular features 
associated with direct and indirect cost related to work disability and loss of function
3
.  
Management of rheumatoid arthritis has over the years moved away from the typical pyramidal 
approach of using simple analgesia as first line pharmacological therapy stepping up therapy 
with disease modifying anti-rheumatic drugs at a later stage.  Radiological evidence that erosions 
occur within the first two years of the condition led to physicians aiming for early treatment and 
treatment to target
4-5
.   
The pharmaceutical research and development of biological agents, such as tumour necrosis 
factor inhibitors, monoclonal antibodies and interleukin inhibitors, has led to the inversion of the 
pyramidal approach.  The current management of rheumatoid arthritis therefore focuses on early 
aggressive treatment using disease modifying agents and biological agents early on to slow the 
disease progression if not to stop disease progression and afford remission
6
.  Patient safety is a 
major feature in management decisions. The increasing effectiveness of drug therapy in current 
disease management is brought about by new classes of agents acting at a fundamental 
inflammatory level (‘biologicals’) and by earlier more aggressive treatment to markedly reduce 
the rate of progression if not stop disease progression in certain instances. Treatment must be 
individualised and patients helped to be actively involved in their own management and 
monitoring for effectiveness and safety. This could be achieved through a pharmaceutical care 
service. The context above raises questions about how to achieve optimal care within a 
multidisciplinary setting in which specialist pharmacists are providing new services requiring 
networking arrangements to underpin the quality of care as the patient moves between clinical 
settings, home, hospital, and clinic.  
In Malta the chronic disease management of patients with rheumatoid arthritis is delivered via a 
specialist physician multidisciplinary team that has included a pharmacist since 2003. Newly 
diagnosed patients are referred to the consultants’ rheumatology clinic via general practitioners 
or hospital specialists in other disciplines. The multidisciplinary rheumatology team also 
includes specialist nurse, occupational therapist, physiotherapist and podologist.  The pharmacist 
input has been developing over the past seven years via inpatient services. The aim of this study 
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was to evaluate the impact of a newly developed pharmaceutical care service within a 
multidiscplinary rheumatology outpatients service.  
MATERIALS AND METHODS 
Patient recruitment  
The study was approved by the Research Ethics Committee. Rheumatoid arthritis adult patients 
who were on methotrexate regularly attending the Rheumatology Out-Patient Clinic were 
eligible to participate in the study. patients were excluded if they were unable to read or 
understand English or Maltese, suffered from a mental health problem, or refused to give their 
written informed consent. 
A total of 96 patients were randomly assigned to two equal groups (A and B) and followed up in 
parallel for 11 months. The patients completed health related quality of life questionnaires at 
baseline and at each clinical assessment visit. Pharmaceutical clinical assessments were carried 
out at outpatient appointments fixed twice between 4-8 months and between 10-11 months 
during the 11 month study. Pharmaceutical care assessment involving the establishment of a care 
plan was conducted at baseline entry to the study (time zero; Group A) or at the 4-8 month visit 
(Group B). Study group A therefore provided a pre-test baseline health related quality of life 
measurement followed by two post-test measurements. Study group B received a pharmaceutical 
care assessment and care plan after two pre-test health related quality of life measurements at 
zero and 4-8 months and the group provided a post-test measurement at 2-7 months (at the 10-11 
month point in the 11 month study). The study design allowed for each of the group to act as 
control within itself as well as to provide a comparison of parallel active and control phases. 
Prior to patient contact the pharmacist-researcher developed an information leaflet on 
methotrexate therapy in English and Maltese. The compiled leaflet which was validated by an 
expert panel consisting of the rheumatology clinic medical team was designed to be easily 
understood by patients and their careers.   
The pharmaceutical care consultation 
A pharmaceutical care consultation led to the identification of pharmaceutical care issues.  The 
session focused on determining whether all patient’s drug therapy was the most appropriate, safe, 
effective and conveniently available for the patient During the pharmaceutical care consultation, 
the clinical pharmacist identified pharmaceutical care issues. These were then classified as drug 
therapy problems according to the Strand et al classification
7
 and further subdivided into actual 
and potential drug therapy problems according to a categorization system developed by 
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colleagues
8-9
 at the Strathclyde Institute of Pharmacy and Biomedical Sciences, at the University 
of Strathclyde . Actual drug therapy problems are problems which are present and hence need to 
be resolved immediately whereas potential drug therapy problems are problems which are not 
yet present but which might arise in future and which could be avoided if the correct action is 
taken
10
 The category non-drug therapy problems was added to the list to accommodate 
pharmaceutical care issues which were not directly related to drug therapy but relied on patient’s 
perception, information on treatment or the need of other help from other health care 
professionals.  Actions (checks or changes) needed to resolve each care issue problem were 
documented in the care plan within the patient’s medical file.  
All patients were counseled on methotrexate therapy and given a copy of the developed leaflet. 
The pharmaceutical care session was documented on a pharmaceutical care form developed for 
the purpose of the study.  A referral form was also designed for the purpose of the study.  The 
referral form documented in point form the type of drug therapy problem identified during the 
session and action taken or suggested to resolve the problem.  The referral form was used as an 
easy way of documenting and retrieving information for use by the medical prescriber.  
Statistical analysis 
The evaluation of the pharmaceutical care session was studied using the Health Assessment 
questionnaire and the SF36 questionnaire. Data was analyzed using SPSS version 7 and the 
Wilcoxon test was undertaken. 
RESULTS AND DISCUSSION 
A total of 88 patients were recruited in the study since eight patients failed to attend for their first 
appointment. The mean (SD) age of the patients was 60.8 (11.6) years. The mean number of 
years on methotrexate was 10 years. Both groups were found to be statistically similar. 
Approximately 84% (n=74) of the patients stated that the information leaflet was found to be 
useful and 89% (n=78) stated that the leaflet was self-explanatory. Comments were received 
from 74% (n=65) of the patients, 85% (n=55) of whom stated that the leaflet was a good 
initiative and 15% (n=10) of whom stated that they would appreciate similar leaflets on other 
drugs, the role of physiotherapy and the role of occupational therapy in rheumatoid arthritis 
(Figure 1).   
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Figure 1.  Evaluation of the information leaflet 
A total of 106 pharmaceutical care issues were identified for the 88 patients giving a mean of 1.2 
per patient where 72% (n=76) were actual drug therapy problems requiring alteration of the 
therapeutic plan and 28% (n=30) were potential drug therapy problems requiring resolution by 
reference back to the therapeutic plan.  This data contrasts to similar studies carried out in cancer 
care patients
11
 and in rheumatoid arthritis patients
10
 in the United Kingdom where the majority of  
pharmaceutical care issues were classified as checks This difference could be explained because 
in this study the pharmacist researcher was easily accessible being present at the clinic with the 
medical team hence being directly involved in discussions regarding drug therapy to be 
prescribed.  Such discussions resulted in a higher number of changes rather than checks.  
Another reason for the low number of checks could be well due to the role of the specialist nurse 
at the clinic who carried out monitoring of the patients including checking of routine laboratory 
tests to identify potential problems, as well as assessed the general well being of the patients as 
influenced by rheumatoid arthritis.   
The results of the health assessment questionnaire showed an improvement in the daily activities 
associated with an intervention compared with baseline with overall score improvements (Table 
1). The results of the SF 36 showed that overall there was significant improvement in all the 8 
domains of the SF36 after the intervention (Table 2). For Group A patients there was a 
statistically significant improvement at time 4 months (Phase 2) following the pharmaceutical 
session for six of the eight domains of quality of life namely role physical, bodily pain, social 
function, vitality, general health and mental health. This improvement in the quality of life 
effected by these six domains further improved over time at Phase 3. In contrast the domain 
physical function and role emotion showed a statistically significant improvement at Phase 3 
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indicating a longer term.  Group B patients showed no difference and no improvement in all the 
eight domains of the SF36 between Phase 1 and Phase 2 prior to any pharmaceutical sessions. 
There was a statistically significant improvement in all the eight domains of the SF36 between 
Phase 2 and Phase 3 following a pharmaceutical contribution by the pharmacist. 
Table 1.  Statistical analysis for Health Assessment Questionnaire 
Positive and negative mean rank score (p value) 
Group  A Phase 1 – Phase 2 Phase 2- Phase 3  Phase 1- Phase 3 
 8.8-10.2 (0.767) 11.3-11.0 (0.001)* 9.3-11.2 (0.001)* 
Group B Phase 1 – Phase 2 Phase 2- Phase 3   
 1.0-3.0 (0.141) 8.5-11.6 (<0.001)*  
**p value  from Wilcoxon signed rank test (p>0.05) 
Table 2 Statistical analysis for the SF36, p value 
Group A Phase 1 – Phase 2 Phase 2- Phase 3 Phase 1- Phase 3 
Domain    
Physical Function  0.301 <0.001 <0.001 
Role Physical  0.03 0.00 0.001 
Role Emotion  0.07 0.157 0.019 
Bodily Pain  <0.001 <0.001 <0.001 
Social Function  0.004  0.001 <0.001 
Vitality  0.007 <0.001 <0.001 
General Health  <0.001 <0.001 <0.001 
Mental Health <0.001 <0.001 <0.001 
*p value  from Wilcoxon signed rank test (p>0.05) 
This study attempted to evaluate the impact of the provision of professional pharmacy services 
within a pharmaceutical care model in an out-patient setting.  Two health related questionnaires 
were chosen as a measuring tool to assess the impact of the pharmacist’s contribution on the 
quality of life of rheumatoid arthritis patients.  The decision to adopt the Health Assessment 
Questionnaire and the SF36 was based on literature review which demonstrated the tools’ 
validity and reliability.
10,12-17
 The tools also proved practical and applicable within the local set 
up making it feasible to incorporate the use of these tools within a framework of service 
provision.  
For group A patients the results indicate that there was an improvement in the quality of life of 
the patients reflected by a decrease in the health assessment questionnaire score which occurred 
following the pharmacist’s intervention during the pharmaceutical intervention at Phase 1. This 
improvement in the quality of life of the patients increased over time (Phase 3) meaning that the 
impact of the pharmacist’s intervention through individualized pharmaceutical care showed a 
further improvement in the quality of life of patients on a longer term.   
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Group B patients registered a statistically significant improvement in their health assessment 
questionnaire score following a pharmaceutical care session which mirrors the fact that 
pharmacist intervention improves quality of life.   
From the results of the Short Form 36 analysis, the impact of the pharmacist’s contribution after 
11 months resulted in an improvement of quality of life.  However for some domains namely 
physical function and role emotion this impact may take longer to result in an improvement.  The 
results from Group B patients mirrored those of Group A. 
CONCLUSION 
Pharmaceutical care services offered within a rheumatology out-patient clinic multidisciplinary 
team can help to improve the patients’ quality of life. This study has confirmed the positive 
impact of the pharmacist intervention within this multidisciplinary team on the patients’ quality 
attending the rheumatology out-patient clinic. This has been confirmed in other studies in other 
areas such as in the management of cardiovascular patients and diabetes patients
18-23
. Processes 
to identify patients who would require pharmaceutical care services within the setting may need 
to be identified in the scenario that the pharmaceutical care services are offered to all patients 
attending the clinic. Research to standardize the pharmaceutical care services is now being 
undertaken to ensure a harmonized evidence based quality service. 
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